OTLC.US Oncotelic Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0100 USD
Close of Nov 15, 2026
0.0100 0.1000
Market cap
USD 4.58M
P/E
0.0x
P/B
0.02x
ROE
-1.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is OTLC.US undervalued?

Graham number

The Graham number of Oncotelic Therapeutics Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oncotelic Therapeutics Inc fundamental analysis

No fundamental analysis for Oncotelic Therapeutics Inc yet.

Oncotelic Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oncotelic Therapeutics Inc

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, m…

Full company profile